Clinical Trial Update: Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase [Phase 1]

View source ↗

Summary

A Phase I trial evaluating dasatinib in combination with imatinib for chronic myeloid leukemia in chronic phase has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)
• Imatinib (imatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Myeloid Leukemia, Chronic, Chronic-Phase | Phase 1 | Status: WITHDRAWN